Original articlesMorula transfer as alternative to blastocyst transfer or day 3 transfer is there a role?Nada, Adel M.; Khalil, Reham F.; Sawaf, Ahmed; El-halwagy, Ahmed Author Information Department of Gynecology and Obstetrics, Faculty of Medicine, Cairo University, Cairo, Egypt Correspondence to Adel M. Nada, MD, 24 Abdelrahaman El barkoky-Almanyalst, PO Box 11451, Cairo, Egypt Tel: +20 111 176 5934; e-mail: [email protected] Received June 4, 2014 Accepted November 17, 2014 Evidence Based Women's Health Journal: February 2015 - Volume 5 - Issue 1 - p 43-46 doi: 10.1097/01.EBX.0000458877.10672.6c Buy Metrics Abstract Objective The aim of this study was to evaluate the clinical outcomes of day 4 embryo transfers (ETs) and compare the efficacy of day 4 ET with day 5 and day 3. Study design All women undergoing ICSI-ET with grade I embryos only were included and divided into: group A with 1224 patients (ET day 3); group B with 159 patients (ET day 4); and group C with 84 patients (ET day 5). Luteal phase support was given to all patients by administering 800 mg cyclogest intravaginally per day for 14 days, starting from Ovum pick up day, and then quantitative β-human chorionic gonadotropin was measured in serum. Pregnant patients were closely followed up till 12 weeks postmenstrual. Results There was no significant difference between ET day 3 and ET day 4 regarding age, duration of infertility, and oocytes retrieved. Clinical pregnancy rate in group A was 37% and in group B 31.4% (P=0.17) compared with group C (ET day 5) where clinical pregnancy rate was 26.2% (P=0.39). Conclusion ET at the morula stage does not affect pregnancy outcome in in-vitro fertilization/ICSI cycles. © 2015 Lippincott Williams & Wilkins, Inc.